High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
-
Published:2022-12
Issue:
Volume:177
Page:80-93
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Dercle LaurentORCID, Ammari Samy, Roblin ElvireORCID, Bigorgne Amelie, Champiat Stéphane, Taihi Lokmane, Plaian Athèna, Hans Sophie, Lakiss Sara, Tselikas Lambros, Rouanne MathieuORCID, Deutsch Eric, Schwartz Lawrence H., Gönen Mithat, Flynn Jessica, Massard Christophe, Soria Jean-Charles, Robert Caroline, Marabelle Aurélien
Subject
Cancer Research,Oncology
Reference44 articles.
1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017 2. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015 3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018 4. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial;Shitara;Lancet,2018 5. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat Rev Cancer,2019
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|